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Previewsshowed clinical resistance to ponatinib.
However, 22 cases of compound muta-
tions without T315I patterns of variable
effectiveness was demonstrated across
the panel of TKIs, which suggests that
early detection of compound mutations
could be combined with sensitivity
studies to shape a therapeutic change in
TKIs and thus abort the emergence of
resistant clones.
Computer modeling suggested the
impact of compoundmutations on TKI ac-
tivity. The proliferation studies noted
above found that, for compound muta-
tions not containing T315I, ponatinib
anddasatinib had similar activities, except
with the Y253H/E55V compound muta-
tion, where dasatinib is considerably
more active. The binding sites of ponatinib
and dasatinib are known to be different;
can modeling explain the difference?
Indeed, it can; molecular dynamic simula-
tions showed that Y253H and E255V mu-
tations force a shift in the P loop of the
ABL kinase domain, obstructing the pona-
tinib binding site. Similar simulations sug-306 Cancer Cell 26, September 8, 2014 ª201gested poor ponatinib activity in clinically
relevant disease evolution, such as thedif-
ference in the binding domains of a single
T315I and the resistant T315I/E255V
mutation. Thus, the authors elegantly fol-
lowed the interplay of structure, in vitro
and in vivo function.
Why is this study important? First, it is a
demonstration of how clinical material,
wet bench work, and computer modeling
can be melded to develop a clear under-
standing of clinically important biology.
Second, it provides a clear roadmap of
how future studies can be performed to
understand disease resistance. As ‘‘tar-
geted therapy’’ becomes an increasing
reality in cancer care, it will become
increasingly important to understand
and anticipate how Darwinian selection
will select for resistance. This manuscript
helps prepare us for that future.REFERENCES
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A better understanding of genetic interactions in cancer might help identify new therapeutic approaches that
exploit the concept of synthetic lethality. Ruppin and colleagues have developed a new computational
method, DAISY, that predicts such interactions and potentially facilitates the delineation and validation of
comprehensive genetic interaction networks.Most of the major recent advances in the
development of targeted therapies for
cancer have originated from the identifica-
tion and exploitation of genetic depen-
dencies that operate specifically in tumor
cells. Many of these dependencies are
considered as oncogene addiction ef-
fects, where tumor cells become reliant
upon the activity of key driver genes
such as BCR-ABL and EGFR; pharma-cological inhibition of these drivers has
therapeutic benefit. Other dependencies
include those that arise as a consequence
of the ‘‘cancer state,’’ also called nonon-
cogene addictions (Luo et al., 2009). How-
ever, inmany cases these gene addictions
are difficult to target directly with drugs.
Moreover, there aremany recessive driver
mutations in tumor genomes, the so-
called tumor suppressors, in which absentor reduced gene function contributes to
tumorigenesis. Synthetic lethality (SL)
provides a potential approach to targeting
these latter two classes of alterations. The
term describes the relationship between
two genes whereby individual defects in
either gene are compatible with cell
viability, but the synthesis or combination
of gene defects results in cell death (Ash-
worth et al., 2011). Recently the
Figure 1. The DAISY Approach to Predicting SL
DAISY integrates information from three data sources—copy number profiles from tumors and tumor cell lines, gene expression profiles, and tumor cell line
shRNA screens—to predict SL effects.
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Previewsexploitation of SL effects involving tumor
suppressor genes such as BRCA1 or
BRCA2 in cancer cells has led to the
development of new therapeutic ap-
proaches (Lord and Ashworth, 2012).
In yeast and other model organisms,
high-throughput reverse genetic screens
have enabled the systematic mapping of
SL networks on a genome-wide scale
(Dixon et al., 2009). In human cancer cell
lines, RNA interference (RNAi) and small
molecule screens have also been em-
ployed to identify SL effects of potential
therapeutic value (Sandmann and Bou-
tros, 2012). Although such screens have
proven useful, they have largely focused
on the identification of genetic interactions
with individual genes or drugs. More sys-
tematic approaches have recently been
developed (Hart and Moffat, 2013), butthese are not yet as robust as those in
more genetically tractable organisms. As
a complement and alternative to these
relatively elaborate experimental studies,
computational methods for predicting
SLs would be beneficial. In model sys-
tems, many predictive approaches have
been proposed, but these primarily focus
on extending experimentally derived SL
networks rather than de novo prediction
of interactions (Wong et al., 2004), limiting
their utility for cancer.
In a recent issue of Cell, Jerby-Arnon
et al. (2014) describe a new computational
approach termedDAISY (datamining syn-
thetic lethality identification pipeline) that
aims to facilitate the large-scale identifica-
tion of SLs in cancer. DAISY is elegantly
built upon three principles. The first,
termed ‘‘genomic survival of the fittest’’Cancer Cell 26, S(gSOF) makes the assumption that SL be-
tween two genes can be discovered by
identifying pairs of genes whose coinacti-
vation in tumorsoccursmuch less thanex-
pected by chance alone; the premise is
that cells with inactivation in both partners
of a SL pair have a survival disadvantage
and thus are rarely observed. Similar ap-
proaches based on ‘‘mutually-exclusive’’
mutations have previously been proposed
(Ciriello et al., 2012), but large-scale
benchmarking and evaluation of results
has been lacking. The second component
ofDAISYexploits publishedgenome-wide
short-hairpin RNA (shRNA) screens per-
formed inpanels of human tumor cell lines.
By combining these data with genomic
and transcriptomic profiles of each cell
line model, SL pairs were captured by
seeking shRNAs that specifically causeeptember 8, 2014 ª2014 Elsevier Inc. 307
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Previewscell inhibition when a particular gene has
either reduced expression or reduced
copy number. Finally, a third approach ex-
ploits the observation that SL pairs
frequently engage in functionally related
processes and are therefore often coex-
pressed. Each of these three heuristics is
used independently to assign an interac-
tion score for each gene pair using a vari-
ety of expression, copy number, and
shRNA data sets. These scores are then
integrated to predict candidate SLs
(Figure 1). In addition to SL, Jerby-Arnon
et al. (2014) use the sameapproach topre-
dict what they term ‘‘synthetic dosage le-
thal’’ (SDL) interactions, where overex-
pression of one gene (for example, driven
by copy number amplification) renders a
second gene essential.
To validate their approach, they first
demonstrated that DAISY is capable of
predicting dependencies previously iden-
tified by RNAi experiments in human cell
lines. They evaluated each feature (coex-
pression, gSOF, and shRNA results) indi-
vidually and found that a combination
of the three proves to be the strongest pre-
dictor and that data from shRNA screens
in large cell line collections offer little
predictive power on their own. To further
demonstrate the utility of DAISY, they pre-
dicted novel SLs for the tumor suppressor
VHL and validated a number of these
using either siRNAs or drugs. Having
shown DAISY capable of predicting
known and novel SLs, they applied their
algorithm on a genome-wide scale to
predict high-confidence SL and SDL net-
works encompassing 3,000 SL and
3,600 SDL interactions. Although these
data have considerable utility, a weighted
network containing interactions that pass
some but not all criteria might also be
beneficial to those planning to experimen-
tally test interactions associated with spe-
cific genes.
Subsequent analyses in the paper high-
light the utility of the SL and SDL high-308 Cancer Cell 26, September 8, 2014 ª201confidence networks in predicting both
patient and cell line phenotypes. The SL
network is applied to predict the sensi-
tivity of cell lines to RNAi of specific
genes, while the SDL network is used for
predicting sensitivity to specific drugs. A
drug targeting a specific gene is predicted
to impact growth if its SDL partner is over-
expressed in the cell line being measured.
This effect is shown to be cumulative—
the greater the number of SDL partners
of a gene are overexpressed, the more
likely that a drug targeting a gene is to
impact cell growth, suggesting that the
predicted interactions may be synthetic
sick (causing a growth defect) rather
than SL (causing cell death).
In an indirect validation of the predicted
networks, the authors suggest that tumors
with low expression of two SL partners
should have reduced fitness, potentially
indicating an improved outcome for pa-
tients. Using a large cohort of breast can-
cer patients, the authors demonstrate that
this might indeed be the case; patients
with tumors underexpressing two SL part-
ners have a better overall survival. This ef-
fect is also cumulative; the more SL pairs
a tumor underexpresses, the better the
outcome.
In the present study, the authors have
focused primarily on SLs and SDLs as-
sociated with copy number alterations
(loss and amplification respectively).
This approach enables uniform applica-
tion of the DAISY algorithm to all genes
in a variety of copy-number data sets.
However, many tumor suppressors and
the majority of oncogenes are subject to
more subtle missense mutations (Vogel-
stein et al., 2013), and information on
these are largely missing from the pre-
dicted SL networks. In principle, there is
no reason that the DAISY approach
cannot be applied in a more fine-grained
approach to identify synthetic depen-
dencies associated with specific onco-
genic mutations.4 Elsevier Inc.Perhaps the most promising aspect
of the DAISY approach is that it relies
primarily on data from sequencing and
gene expression studies. As the number
of patient and cell line samples with
such data available is increasing expo-
nentially, we can expect significant im-
provements in the accuracy and coverage
of the predicted SL networks. This may
facilitate the identification of SL inter-
action partners for rare driver muta-
tions. For more commonly mutated genes
(e.g., KRAS, PTEN), it may become
possible to identify higher-order depen-
dencies (e.g., gene X is essential if KRAS
and APC are both mutated) of therapeutic
relevance.REFERENCES
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